Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...

Royal woman must abide by a long list of rules. But when Meghan Markle arrived at the British Fashion Awards and Kate Middleton attended a church service, both threw out the royal rule book.

George House Trust, a charity supporting people to live well and confidently with HIV across Greater Manchester, Liverpool ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center, collaborates with researchers from the Kenya Medical Research Institute ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...

PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

Disparities in HIV diagnosis rates were observed between Black and White individuals in the US from 2017 to 2021.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...